Artificial intelligence is shaping breakthroughs in drug development and diagnostics. Researchers at MIT introduced COMET, a transformer-based machine learning model that accelerates design of lipid nanoparticles for RNA therapies, promising to quicken vaccine and therapeutic development. Meanwhile, Johns Hopkins scientists developed MIGHT, an AI methodology delivering unmatched reliability and interpretability suited for high-stakes medical diagnostics, addressing critical needs for clinical deployment. Additionally, GoodRx partnered with Novo Nordisk to improve accessibility of GLP-1 drugs through pharmacy discount programs, integrating AI-driven market strategies to address affordability.